Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MERCEDES E GONZALEZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1750563243
CMS profile
306248
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$28,485.25

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MERCEDES E GONZALEZ

NPI 1750563243 · CMS profile ID 306248

Allopathic & Osteopathic Physicians / Dermatology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MERCEDES E GONZALEZ, NPI 1750563243, CMS profile ID 306248, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750563243?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $28,485.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $88.4807/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842194427 CMS
Galderma Laboratories, L.P. $20.1107/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855276761 CMS
SANOFI-AVENTIS U.S. LLC $65.3706/30/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843670635 CMS
PFIZER INC. $20.0606/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832572429 CMS
Novartis Pharmaceuticals Corporation $20.1506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812696713 CMS
Lilly USA, LLC $28.8106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818645043 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.2106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849561837 CMS
Regeneron Healthcare Solutions, Inc. $25.5906/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581919 CMS
GENZYME CORPORATION $24.7905/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843670643 CMS
PFIZER INC. $22.2205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832645611 CMS
Lilly USA, LLC $20.2905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818660783 CMS
GENZYME CORPORATION $21.7304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843670621 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.4604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851911175 CMS
Regeneron Healthcare Solutions, Inc. $26.3304/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581917 CMS
TOLMAR Pharmaceuticals, Inc. $18.0404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836498039 CMS
PFIZER INC. $20.3304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832653855 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.8203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851911173 CMS
Lilly USA, LLC $17.9703/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669915 CMS
SANOFI-AVENTIS U.S. LLC $24.9703/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843670617 CMS
AbbVie Inc. $24.4703/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794633379 CMS
DERMIRA, INC. $15.6803/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 764403608 CMS
PFIZER INC. $22.3003/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832560937 CMS
Alexion Pharmaceuticals, Inc. $22.8002/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783116117 CMS
Xeris Pharmaceuticals, Inc. $16.3402/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837423533 CMS
Lilly USA, LLC $12.5401/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818642279 CMS
PFIZER INC. $19.0101/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832572207 CMS
Regeneron Healthcare Solutions, Inc. $260.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581895 CMS
Regeneron Healthcare Solutions, Inc. $260.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581897 CMS
Regeneron Healthcare Solutions, Inc. $520.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581899 CMS
Regeneron Healthcare Solutions, Inc. $520.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581901 CMS
Regeneron Healthcare Solutions, Inc. $1,040.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581903 CMS
Regeneron Healthcare Solutions, Inc. $520.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581905 CMS
Regeneron Healthcare Solutions, Inc. $520.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581907 CMS
Regeneron Healthcare Solutions, Inc. $520.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581909 CMS
Regeneron Healthcare Solutions, Inc. $260.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581911 CMS
Regeneron Healthcare Solutions, Inc. $3,380.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581913 CMS
Regeneron Healthcare Solutions, Inc. $104.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581915 CMS
GENZYME CORPORATION $1,967.0001/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843670599 CMS
Regeneron Healthcare Solutions, Inc. $25.3501/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809581893 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $116,495.56 155
PY2020 $23,384.39 60
PY2021 $28,485.25 89
PY2022 $34,229.74 110
PY2023 $137,827.89 175
PY2024 $262,679.80 251
PY2025 $339,861.38 364

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $117,937.37 9
PY2025 Principal investigator $884,331.45 126
PY2024 Recipient $171,734.08 6
PY2024 Principal investigator $638,630.46 249
PY2023 Principal investigator $485,149.65 198
PY2022 Recipient $11,033.02 26
PY2022 Principal investigator $102,177.16 50
PY2021 Recipient $599.27 2
PY2021 Principal investigator $225,999.25 42
PY2020 Principal investigator $161,571.53 38
PY2019 Principal investigator $143,668.56 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

135 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $14,000.00 12/25/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 No dispute reported 06/30/2026 1228746725
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129089
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129093
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129098
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129102
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129106
Principal investigator 1 SANOFI US SERVICES INC. $658.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129111
Principal investigator 1 SANOFI US SERVICES INC. $541.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129114
Principal investigator 1 SANOFI US SERVICES INC. $541.00 12/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226129118
Principal investigator 1 Incyte Corporation $1,543.50 12/19/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576473
Recipient Nielsen BioSciences, Inc. $111,668.37 12/15/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1215547454
Principal investigator 1 SANOFI US SERVICES INC. $30,621.00 12/15/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126289
Principal investigator 1 PFIZER INC. $6,331.15 12/11/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228725548
Principal investigator 1 SANOFI US SERVICES INC. $4,819.00 12/08/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126285
Principal investigator 1 ABBVIE INC. $4,339.00 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202526824
Principal investigator 1 Incyte Corporation $3,656.20 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576356
Principal investigator 1 Incyte Corporation $3,429.00 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576362
Principal investigator 1 Incyte Corporation $6,556.60 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576367
Principal investigator 1 Incyte Corporation $4,930.60 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,602.70 12/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184269459
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,156.80 12/01/2025 Non-covered Recipient Entity
PEDIATRIC DERMATOLOGY OF MIAMI AT THE PEDIATRIC COE
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190309142
Principal investigator 1 Incyte Corporation $1,805.40 11/26/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576466
Principal investigator 1 Incyte Corporation $1,465.20 11/25/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576296
Principal investigator 1 PFIZER INC. $23,753.45 11/25/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228727965
Principal investigator 1 PFIZER INC. $1,065.00 11/19/2025 Non-covered Recipient Entity
Mercedes E Gonzalez MD
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228739985
Principal investigator 1 PFIZER INC. $1,065.00 11/19/2025 Non-covered Recipient Entity
Mercedes E Gonzalez MD
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228748171
Principal investigator 1 SANOFI US SERVICES INC. $48,309.00 11/17/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126276
Principal investigator 1 SANOFI US SERVICES INC. $7,901.80 11/17/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126281
Principal investigator 1 Incyte Corporation $1,815.30 11/13/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576462
Principal investigator 1 SANOFI US SERVICES INC. $8,838.50 11/10/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126272
Principal investigator 1 Incyte Corporation $2,542.50 11/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,371.61 11/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184257865
Principal investigator 1 ABBVIE INC. $9,929.45 11/05/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523071
Principal investigator 1 Incyte Corporation $75.00 11/01/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576350
Principal investigator 1 PFIZER INC. $31,611.30 10/29/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228720749
Recipient GENZYME CORPORATION $500.00 10/24/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226127070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $579.36 10/23/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252798
Principal investigator 1 Incyte Corporation $7,710.30 10/16/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576450
Principal investigator 1 Eli Lilly and Company $8,620.00 10/14/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187887602
Principal investigator 1 ABBVIE INC. $100.00 10/09/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514497
Principal investigator 1 Incyte Corporation $1,270.80 10/09/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576282
Principal investigator 1 Incyte Corporation $1,805.40 10/09/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576455
Principal investigator 1 PFIZER INC. $14,000.00 10/08/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228729904
Principal investigator 1 SANOFI US SERVICES INC. $17,386.60 10/06/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126248
Principal investigator 1 Incyte Corporation $1,963.80 10/03/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,002.42 10/03/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244813
Principal investigator 1 SANOFI US SERVICES INC. $13,538.00 09/29/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126243
Principal investigator 1 Incyte Corporation $310.50 09/23/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576270
Principal investigator 1 SANOFI US SERVICES INC. $1,580.00 09/23/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126252
Principal investigator 1 SANOFI US SERVICES INC. $658.00 09/23/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126255
Principal investigator 1 SANOFI US SERVICES INC. $658.00 09/23/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126260
Principal investigator 1 SANOFI US SERVICES INC. $658.00 09/23/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126264
Principal investigator 1 SANOFI US SERVICES INC. $541.00 09/23/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126268
Recipient GENZYME CORPORATION $500.00 09/17/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226127061
Principal investigator 1 Incyte Corporation $1,963.80 09/12/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576274
Principal investigator 1 PFIZER INC. $16,400.00 09/09/2025 Non-covered Recipient Entity
Pediatric Skin Research LLC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228750502
Principal investigator 1 ABBVIE INC. $2,458.55 09/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202509202
Principal investigator 1 Incyte Corporation $3,429.00 09/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576264
Principal investigator 1 Incyte Corporation $1,805.40 09/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576446
Principal investigator 1 SANOFI US SERVICES INC. $8,472.50 09/03/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126238
Recipient PFIZER INC. $940.00 08/29/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727769
Principal investigator 1 Incyte Corporation $4,574.00 08/26/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576432
Principal investigator 1 SANOFI US SERVICES INC. $33,223.00 08/25/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126234
Principal investigator 1 Incyte Corporation $3,487.50 08/21/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576428
Principal investigator 1 Incyte Corporation $3,041.10 08/14/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576252
Principal investigator 1 Incyte Corporation $3,487.50 08/14/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576439
Principal investigator 1 Arcutis Biotherapeutics, Inc. $18,157.50 08/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH, LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163786
Principal investigator 1 Incyte Corporation $1,387.80 08/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.63 08/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184226337
Principal investigator 1 ABBVIE INC. $6,651.75 08/06/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202502901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $531.08 07/31/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184222974
Principal investigator 1 Incyte Corporation $621.00 07/17/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576245
Principal investigator 1 Incyte Corporation $18,296.00 07/17/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576422
Principal investigator 1 SANOFI US SERVICES INC. $4,834.00 07/14/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126221
Principal investigator 1 SANOFI US SERVICES INC. $26,049.90 07/14/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126226
Principal investigator 1 Incyte Corporation $2,425.50 07/10/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576239
Principal investigator 1 Incyte Corporation $1,543.50 07/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,953.13 07/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184213013
Principal investigator 1 ABBVIE INC. $10,044.30 07/02/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202494171
Principal investigator 1 SANOFI US SERVICES INC. $31,852.00 07/02/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126197
Principal investigator 1 SANOFI US SERVICES INC. $2,640.99 07/02/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226126217
Principal investigator 1 SANOFI US SERVICES INC. $16,473.60 07/02/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126230
Principal investigator 1 Arcutis Biotherapeutics, Inc. $10,000.00 06/23/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH, LLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163784
Principal investigator 1 SANOFI US SERVICES INC. $658.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126189
Principal investigator 1 SANOFI US SERVICES INC. $658.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126193
Principal investigator 1 SANOFI US SERVICES INC. $658.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126202
Principal investigator 1 SANOFI US SERVICES INC. $541.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126205
Principal investigator 1 SANOFI US SERVICES INC. $541.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126209
Principal investigator 1 SANOFI US SERVICES INC. $541.00 06/20/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126214
Principal investigator 1 Incyte Corporation $1,963.80 06/19/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576233
Principal investigator 1 Incyte Corporation $3,528.90 06/19/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576410
Principal investigator 1 Incyte Corporation $1,077.30 06/12/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576227
Principal investigator 1 ABBVIE INC. $100.00 06/03/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202489189
Recipient GENZYME CORPORATION $500.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226127057
Recipient GENZYME CORPORATION $250.00 05/29/2025 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226127066
Principal investigator 1 Incyte Corporation $2,309.40 05/28/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,325.49 05/28/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184199003
Principal investigator 1 Incyte Corporation $1,077.30 05/22/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576329
Principal investigator 1 Incyte Corporation $2,425.50 05/15/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576337
Principal investigator 1 Incyte Corporation $2,274.30 05/08/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,611.60 05/08/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184193807
Principal investigator 1 ABBVIE INC. $30,682.35 05/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202483955
Recipient PFIZER INC. $330.00 05/06/2025 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228722576
Principal investigator 1 Incyte Corporation $1,077.30 04/28/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576317
Principal investigator 1 Incyte Corporation $1,985.40 04/28/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576404
Principal investigator 1 SANOFI US SERVICES INC. $33,654.30 04/28/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126181
Principal investigator 1 Incyte Corporation $1,805.40 04/23/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576396
Principal investigator 1 Incyte Corporation $2,465.10 04/15/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,985.20 04/15/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184183260
Principal investigator 1 SANOFI US SERVICES INC. $4,990.01 04/14/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226126185
Principal investigator 1 ABBVIE INC. $7,705.90 04/03/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202473037
Principal investigator 1 Incyte Corporation $13,839.30 04/01/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576311
Recipient Regeneron Pharmaceuticals, Inc. $2,499.00 04/01/2025 Covered Recipient Physician NEUROPSYCHOLOGIC ASSESSMENTS OF DUPILUMAB-TREATED ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184117865
Principal investigator 1 Incyte Corporation $13,595.40 03/25/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576391
Principal investigator 1 SANOFI US SERVICES INC. $658.00 03/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126173
Principal investigator 1 SANOFI US SERVICES INC. $658.00 03/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226126177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $869.04 03/19/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174424
Principal investigator 1 SANOFI US SERVICES INC. $21,590.00 03/17/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48.28 03/11/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184170768
Principal investigator 1 ABBVIE INC. $14,240.00 03/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202461247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.12 03/04/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184156632
Recipient Regeneron Pharmaceuticals, Inc. $750.00 03/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184117863
Principal investigator 1 SANOFI US SERVICES INC. $30,791.10 02/24/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,875.78 02/18/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184154368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,187.22 02/11/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184153050
Principal investigator 1 Amgen Inc. $77,178.08 02/05/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246646409
Principal investigator 1 Eli Lilly and Company $24,461.75 02/05/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187888128
Principal investigator 1 Amgen Inc. $5,038.54 01/30/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246646413
Principal investigator 1 Incyte Corporation $621.00 01/29/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $482.80 01/21/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149152
Principal investigator 1 SANOFI US SERVICES INC. $16,164.00 01/21/2025 Non-covered Recipient Entity
Pediatric Skin Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226126161
Principal investigator 1 Incyte Corporation $1,465.20 01/17/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240576373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $962.03 01/17/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $962.03 01/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184146036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $337.96 01/07/2025 Non-covered Recipient Entity
PEDIATRIC SKIN RESEARCH LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184146038